Insider Selling: Pulmonx (NASDAQ:LUNG) Insider Sells $14,990.69 in Stock

Pulmonx Corporation (NASDAQ:LUNG) insider Srikanth Radhakrishnan sold 10,483 shares of the firm’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $1.43, for a total transaction of $14,990.69. Following the completion of the transaction, the insider directly owned 170,736 shares in the company, valued at $244,152.48. This trade represents a 5.78% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Pulmonx Stock Performance

LUNG traded down $0.09 during trading on Wednesday, reaching $1.44. 579,968 shares of the company’s stock were exchanged, compared to its average volume of 360,844. The company’s fifty day moving average price is $1.79 and its 200-day moving average price is $1.79. The company has a debt-to-equity ratio of 0.62, a current ratio of 4.86 and a quick ratio of 4.15. Pulmonx Corporation has a fifty-two week low of $1.31 and a fifty-two week high of $8.71.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on LUNG. D. Boral Capital reaffirmed a “buy” rating and set a $14.00 price target on shares of Pulmonx in a research report on Friday, February 20th. Wall Street Zen raised Pulmonx from a “sell” rating to a “hold” rating in a research report on Sunday, November 16th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Pulmonx in a research note on Thursday, January 22nd. Five research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $6.81.

Key Stories Impacting Pulmonx

Here are the key news stories impacting Pulmonx this week:

• Positive Sentiment: Pulmonx closed a five‑year credit facility of up to $60 million with Perceptive Advisors that includes a $40M term loan (with an option for an additional $20M tied to revenue milestones). Management says the financing extends debt maturity to 2031 and strengthens the balance sheet to support commercial and clinical priorities. Article Title
• Positive Sentiment: Q4 results showed improvement vs. a year ago: narrower GAAP loss ($0.25/sh) and adjusted EBITDA loss improved; full‑year 2025 revenue rose to $90.5M (up 8% YoY) and gross margin expanded to ~78% in Q4 — evidence of operating leverage and cost reductions. Article Title
• Neutral Sentiment: Management issued 2026 revenue guidance of $90M–$92M and expects ~75% gross margin with operating expenses $113M–$115M — guidance gives visibility but comes in below some analyst estimates, leaving mixed signals on near‑term topline momentum. Article Title
• Negative Sentiment: Several insiders sold stock on March 2 (including CEO Glendon E. French III, General Counsel David A. Lehman, CCO Geoffrey Beran Rose and Senior staff), representing multiple percent reductions in their holdings — heavy insider selling can pressure sentiment and amplify downside. SEC filings: CEO sale CEO Form 4, Lehman GC Form 4, Beran Rose CCO Form 4, Srikanth Radhakrishnan Form 4
• Negative Sentiment: Q4 U.S. revenue declined (~11% YoY) and total Q4 revenue was down ~5% YoY, signaling softer commercial momentum in Pulmonx’s largest market — the company emphasized a transition plan to reaccelerate U.S. sales, but near‑term growth risk weighed on the stock. Article Title

Hedge Funds Weigh In On Pulmonx

Institutional investors and hedge funds have recently bought and sold shares of the stock. Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of Pulmonx by 32.1% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 218,758 shares of the company’s stock worth $567,000 after purchasing an additional 53,148 shares during the last quarter. ADAR1 Capital Management LLC boosted its position in Pulmonx by 65.7% during the 4th quarter. ADAR1 Capital Management LLC now owns 355,410 shares of the company’s stock valued at $785,000 after buying an additional 140,913 shares during the period. Engineers Gate Manager LP bought a new stake in Pulmonx in the 4th quarter worth $106,000. Susquehanna Portfolio Strategies LLC purchased a new position in shares of Pulmonx in the fourth quarter valued at about $133,000. Finally, Westfield Capital Management Co. LP bought a new position in shares of Pulmonx during the fourth quarter valued at about $409,000. 91.04% of the stock is currently owned by institutional investors.

About Pulmonx

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.